Torrent Pharma - Q4 Better On Operations, Exports To Play Catch Up: Dolat Capital
Tablets sit illuminated during the film-coating process. (Photographer: Krisztian Bocsi/Bloomberg)

Torrent Pharma - Q4 Better On Operations, Exports To Play Catch Up: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Despite subdued revenue growth, Torrent Pharmaceuticals Ltd. reported 30% Ebitda margin and profit after tax of Rs 3.2 billion better than our estimates of 28% and Rs 2.6 billion respectively.

Sluggishness in sales continue to be led by muted exports performance.

U.S. at $37 million was lowest quarterly sales in last four years (30% YoY decline), Brazil (4% YoY decline) partially offset by India (10% YoY growth) led to flattish YoY revenue growth for the quarter.

However, Ebitda margin at 30% was 200 basis points above expectation driven by product mix and lower selling general and administrative spend in India.

Lower tax rate aided profit after tax at Rs 3.2 billion.

Click on the attachment to read the full report:

Dolat Capital Torrent Pharma Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.